Resources

This research paper assesses the impact of (i) incentives for R&D based on providing Intellectual Property (IP) rights protection, (ii) market competition and (iii) other factors including healthcare policies on access to direct acting antivirals (DAA) for hepatitis C in Europe.

The Hepatitis C Coalition is an umbrella group of leading clinicians, patient organisations, professional groups, industry and other interested parties committed to the reduction of morbidity and mortality associated with hepatitis C and its eventual elimination. This collaborative strategy builds on the release of the All-Party Parliamentary Group on Liver Health's 'Eliminating Hepatitis C in England' report and Public Health England's 'Hepatitis C in England: 2018 Report', with the aim of coordinating action by the key stakeholders involved in delivering elimination.

On 7th June 2018, HCV Action and Public Health England (PHE) staged a hepatitis C good practice roadshow in Oxford. The event was designed to showcase and share best practice in the prevention, diagnosis, testing and treatment of hepatitis C, and identify specific issues and potential solutions for tackling hepatitis C in Oxford and the wider South East area.

This report from the London Joint Working Group on Substance Use and Hepatitis C (LJWG) provides results from a pilot project providing point of care testing for hepatitis C to people who inject drugs accessing needle and syringe programmes based at community pharmacies in London. Over half of participants tested positive for hepatitis C antibodies and 78% of those engaging with further assessment in secondary care had chronic hepatitis C and were hepatitis C RNA positive.